Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Indian Drug Policy Expected To Be Approved At Next Meeting

This article was originally published in PharmAsia News

Executive Summary

India's new pharmaceutical policy is expected to be approved at its next meeting, although the date for the meeting has not been set. The Union Minister of Chemical and Fertilisers is considering a draft policy that contains some disagreements between the Chemicals Ministry and the pharmaceutical industry in India over price controls and other provisions. Under the policy as drafted so far, the list of essential medicines under price controls would increase from 74 to 354. The industry has objected to the added inclusions, arguing such a move would adversely affect research and development. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts